Features of inflammatory and cytolytic syndromes and their influence on the development of cardiomyofibrosis in patients with myocarditis with heart failure
Abstract
ABSTRACT. The activity and duration of the inflammatory process in myocarditis affects the severity of the course of myocarditis and determines the development of cardiomyofibrosis, arrhythmias, dilatation syndrome, the occurrence and progression of heart failure. The mechanisms that affect the transition from an active inflammatory process to chronic ventricular dysfunction have not yet been elucidated. Aim. To study the peculiarities of the course of acute myocarditis and the impact on the quality of life of patients, the relationship between indicators of the inflammatory syndrome, cardiomyocyte lysis and heart failure with FGF-23. Materials and methods. The clinical course of acute myocarditis of unknown etiology in 42 adults, laboratory parameters related to the severity of the course and the processes of myocardial fibrosis were analyzed. Statistical processing of the research results was carried out using the StatSoft Statistica v 10.0 program with a known number of observations (n). Spearman's rank correlation coefficient was calculated. Results. Myocarditis was mainly of medium-severe course (69.1%) with heart failure (HF) of II A stage (59.5%). 35.7% of patients had complex rhythm and conduction disorders. A reliable increase in Creatine Kinase-MB and troponin T was established, which was more pronounced in severe myocarditis. Markers of inflammation (СRP, fibrinogen), cardiomyocyte lysis (Creatine Kinase-MB, troponin T) and fibroblast growth factor 23 (FGF-23) were reliably correlated with each other. The inflammatory process in the myocardium contributed to the growth of heart failure, which was confirmed by a reliable correlation of CRP with NT-pro BNP (r=0.64, p<0.001). Conclusions. In patients with acute myocarditis, manifestations of pronounced cytolytic syndrome were established. The inflammatory process was closely related to the lysis of cardiomyocytes and contributed to the development of heart failure. Fibroblast growth factor FGF-23 significantly increased with increasing severity of myocarditis and significantly correlated with markers of inflammation, cardiomyocyte lysis, and heart failure. The quality of life of patients with acute myocarditis significantly decreases with the worsening of the severity of the course of the disease and the severity of heart failure.
Downloads
References
Kovalenko VM, Nesukay EG, Cherniuk SV, Kozliuk AS, Kirichenko RM. Diagnosis and treatment of myocarditis. UJC [Internet]. 9Sep.2021 [cited 16Mar.2023];28(3):67-8. [in Ukrainian]. DOI: https://doi.org/10.31928/1608-635X-2021.3.6788.
Kovalenko VM, Nesukay EG, Cherniuk SV, Polenova NS, Kirichenko RM, Giresh II, Titov EY, Kozliuk AS, Botsiuk YA. Diagnosis of myocarditis as one of the actual problems in cardiology. UJC [Internet]. 1Oct.2020 [cited 16Mar.2023];27(4):78-9. [in Ukrainian]. DOI: http://doi.org/10.31928/1608-635X-2020.4.7889
Valiton V, Carballo D, Seebach JD, Meyer P. La myocardite en. [Myocarditis in 2020]. Rev Med Suisse. 2020; 16(696):1133-1139. French. PMID: 32496701.
Lampejo T, Durkin SM, Bhatt N, Guttmann O. Acute myocarditis: aetiology, diagnosis and management. Clin Med (Lond). 2021; 21(5):e505-e510. DOI: https://doi.org/10.7861/clinmed.2021-0121
Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al. Registro Lombardo delle Miocarditi. Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. Circulation. 2018; 138(11):1088-1099. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.035319
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ Heart Fail. 2020; 13(11):e007405. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.120.007405
Waliany S, Neal JW, Reddy S, Wakelee H, Shah SA, Srinivas S, et al. Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC CardioOncol. 2021; 3(1):137-139. DOI: https://doi.org/10.1016/j.jaccao.2021.01.004
Al-Akchar M, Shams P, Kiel J. Acute Myocarditis. [Updated 2022 Nov 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 28722877.
Escher F, Tschöepe C, Lassner D, Schultheiss HP. Myocarditis and inflammatory cardiomyopathy: from diagnosis to treatment. Turk Kardiyol Dern Ars. 2015; 43(8):739-48. DOI: https://doi.org/10.29328/journal.jccm.1001041
Kim MJ, Jung HO, Kim H, Bae Y, Lee SY, Jeon DS. 10-year survival outcome after clinically suspected acute myocarditis in adults: A nationwide study in the pre-COVID-19 era. PLoS One. 2023; 18(1):e0281296. DOI: https://doi.org/10.1371/journal.pone.0281296
Fu M, Kontogeorgos S, Thunström E, Zverkova Sandström T, Kroon C, Bollano E, Schaufelberger M, Rosengren A. Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to 2014. Sci Rep. 2022; 12(1):1810. DOI: https://doi.org/10.1038/s41598-022-05951-z
Suresh, A., Martens, P. & Tang, W.H.W. Biomarkers for Myocarditis and Inflammatory Cardiomyopathy. Curr Heart Fail Rep. 2022; 19: 346–355. DOI: https://doi.org/10.1007/s11897-022-00569-8
Gilotra NA, Minkove N, Bennett MK, Tedford RJ, Steenbergen C, Judge DP, et al. Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. J Card Fail. 2016; 22(7):583-5. DOI: https://doi.org/10.1016/j.cardfail.2015.12.022
Mohamud Y, Li B, Bahreyni A, Luo H. Mitochondria Dysfunction at the Heart of Viral Myocarditis: Mechanistic Insights and Therapeutic Implications. Viruses. 2023; 15(2):351. DOI: https://doi.org/10.1038/6543
Basso C. Myocarditis. N Engl J Med. 2022; 387(16):1488-1500. DOI: https://doi.org/10.1056/NEJMra2114478
Vasylenko A, Pavlova Yu. Structural and functional changes of the heart in patients with myocarditis with various degrees of heart failure and on the background of treatment. Medicni perspectivi. 2010;15(2):47-53. [in Ukrainian]. Available: http://nbuv.gov.ua/UJRN/Mp_2010_15_2_12
Xuan Y, Chen C, Wen Z, Wang DW. The Roles of Cardiac Fibroblasts and Endothelial Cells in Myocarditis. Front Cardiovasc Med. 2022; 9:882027. DOI: https://doi.org/10.3389/fcvm.2022.882027
Jiang W, Xiong Y, Li X, Yang Y. Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles. Front Cardiovasc Med. 2021; 8:715258. DOI: https://doi.org/10.3389/fcvm.2021.715258
Petit I, Levy A, Estrach S, Féral CC, Trentin AG, Dingli F, et al. Fibroblast growth factor-2 bound to specific dermal fibroblast-derived extracellular vesicles is protected from degradation. Sci Rep. 2022; 12(1):22131. DOI: https://doi.org/10.1038/s41598-022-26217-8
Ishigami J, Honda Y, Karger AB, Coresh J, Selvin E, Lutsey PL, Matsushita K. 18-year change in serum intact fibroblast growth factor 23 from midlife to late life and risk of mortality: the ARIC Study. Eur J Endocrinol. 2022; 187(1):39-47. DOI: https://doi.org/10.1016/j.mayocpiqo.2022.03.002
Nakano T, Kishimoto H, Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart. Front Endocrinol (Lausanne). 2023; 14:1059179. DOI: https://doi.org/10.3389/fendo.2023.1059179
Leifheit-Nestler M, Haffner D. Paracrine Effects of FGF23 on the Heart. Front Endocrinol (Lausanne). 2018; 9:278. DOI: https://doi.org/10.3389/fendo.2018.00278
Elzayat RS, Bahbah WA, Elzaiat RS, Elgazzar BA. Fibroblast growth factor 23 in children with or without heart failure: a prospective study. BMJ Paediatr Open. 2023; 7(1):e001753. DOI: https://doi.org/10.1136/bmjpo-2022-001753
Hao H, Li X, Li Q, Lin H, Chen Z, Xie J, et al. FGF23 promotes myocardial fibrosis in mice through activation of β-catenin. Oncotarget. 2016; 7(40):64649-64664. DOI: https://doi.org/10.18632/oncotarget.11623
Heymans S, Eriksson U, Lehtonen J, Cooper LT Jr. The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy. J Am Coll Cardiol. 2016; 68(21):2348-2364. DOI: https://doi.org/10.1016/j.jacc.2016.09.937
